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Introduction
Stem-cell therapies have shown great promise for the regen-
eration of a wide range of tissues lost to trauma or disease. 
Several approved stem-cell therapies are currently undergo-
ing clinical trials, and routine procedures such as blood 
transfusions and bone marrow transplantation have now 
been applied in clinical practice for decades. However, 
despite the significant promise offered by these approaches, 
there are considerable limitations restricting their wider 
application. These restrictions primarily relate to the low 
availability of stem cells within donor tissues, loss of 
potency following expansion, regulatory issues surrounding 
translation and even questions surrounding their precise 
mode of action (MoA).1 Significantly, there is evidence to 
suggest that only a small percentage (1%–3%) of stem cells 
actually engraft to the host tissue and that the majority may 
not reach their target sites, instead becoming trapped in the 
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Abstract
Extracellular vesicles comprise a heterogenous population of exosomes and microvesicles that have critical roles in 
intercellular signalling and tissue development. These complex particles have been implicated as mediators of the 
therapeutic effects of stem cells via the transfer of an assorted cargo of proteins and nucleic acids, which can modulate 
inflammation and enhance endogenous regeneration in a range of tissues. In addition, extracellular vesicles have the 
capacity to be loaded with therapeutic molecules for targeted delivery of pharmaceuticals. The versatility, biostability and 
biocompatibility of extracellular vesicles make them appealing for regenerative medicine and may endow considerable 
advantages over single molecule approaches. Furthermore, since production can be optimised and assessed ex vivo, 
extracellular vesicles present a decreased risk of neoplastic transformation when compared with cell-based methods. 
To date, the contribution of vesicles to tissue development has perhaps been most comprehensively defined within 
hard tissues, such as endochondral bone, where they were first identified in 1969 and henceforth referred to as matrix 
vesicles. Within developing bone, vesicles function as vehicles for the delivery of pro-osteogenic factors and initiate early 
nucleational events necessary for matrix mineralisation. However, advancement in our understanding of the biogenesis 
and characterisation of matrix vesicles has occurred largely in parallel to associated developments in wider extracellular 
vesicle biology. As such, there is a requirement to align current understanding of matrix vesicle–mediated mineralisation 
within the context of an evolving literature surrounding exosomes and microvesicles. In this review, we present an 
overview of current progress and opinion surrounding the application of vesicles in regenerative medicine with a 
primary focus on their potential as an acellular approach for enhancing hard tissue regeneration. This is balanced with 
an assessment of areas where further development is required to maximise their application for regenerative medicine.
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lungs, spleen and liver.2 Following a recent paradigm shift, 
it has been proposed that the therapeutic effects of stem cells 
are largely evoked through paracrine activity rather than 
through engraftment and differentiation. A growing body of 
evidence suggests that paracrine activity is exerted through 
the action of trophic factors as well as nano-sized bioactive 
particles termed extracellular vesicles (EVs).3–6
Over the last decade, EVs have demonstrated consider-
able promise as naturally derived nanoparticles that can 
be utilised for a number of therapeutic applications, which 
include predictive and regenerative medicine (Figure 1). 
EVs are ubiquitous within biological fluids (e.g. blood, 
urine, semen, milk and amniotic fluid), contributing to 
critical physiological and pathological processes such as 
tissue development, regeneration, inflammation and can-
cer metastasis.7 Knowledge of the biological contribution 
of EVs to health and disease dates back to the 1960s.8–10 
However, only in the last decade has the potential of these 
multifaceted particles become fully appreciated, with an 
exponential increase in the number of publications featur-
ing ‘extracellular vesicles’ and/or ‘exosomes’ (Figure 1). 
Interest has aligned with the establishment of the 
International Society for Extracellular Vesicles (ISEV) 
and its affiliated journal, the Journal of Extracellular 
Vesicles. In line with growing research activity, position 
statements have been published outlining guidelines for 
the definition and analysis of EVs.11,12 These develop-
ments are reminiscent of events in the field of stem-cell 
biology less than a decade earlier when the Mesenchymal 
and Tissue Stem Cell Committee of the International 
Society for Cellular Therapy outlined the minimal criteria 
for defining human mesenchymal stem cells (MSCs).13 
Mirroring progress previously observed with the expan-
sion and translation of stem-cell therapies, a framework is 
now beginning to be established through which EVs may 
have a pronounced influence on the future direction of 
medicine.14 Much like stem cells, these complex bioactive 
particles can be combined with a bioactive scaffold or 
delivery system to enhance endogenous tissue regenera-
tion and resolve inflammation in a host of tissues, includ-
ing the skeletal system.15 In this review, we will outline 
current knowledge surrounding EVs, summarising their 
critical roles in skeletal development, and highlight the 
advantages and challenges of an EV-based approach to 
regenerative medicine.
EVs
History
Wolf and colleagues first acknowledged the presence of 
phospholipid-rich particulates within platelets, originally 
classifying the material as ‘platelet dust’ (Figure 1). It was 
noted that these particulates could be separated by ultracen-
trifugation (UC) and displayed coagulant properties.8 In 
1967, Anderson and Bonucci observed electron-dense 
‘leaf-like’ particles with ‘needle-like’ projections that were 
attached to collagen fibrils within ossifying cartilaginous 
matrix, which they subsequently defined as matrix vesicles 
(MVs).9,10 In the 1980s, the physiological contribution 
of EVs was found to be more widespread, with these 
nano-sized messengers shown to mediate important immu-
nological processes,16 such as antigen presentation17 and 
anti-tumour activity. Today EVs are known to play a wide 
role in intercellular communication and development 
within a number of hard and soft tissues, where they deliver 
a cargo of nucleic acids, peptides and lipids to neighbour-
ing cells and tissues. The provision of these heterogeneous 
biological cargos has been observed to have a downstream 
effect on a variety of molecular functions,18 including the 
signalling and regulation of gene expression in target cells, 
such as the upregulation of proteoglycan and type-II colla-
gen by osteoarthritic chondrocytes.19 More recently, the 
delivery of both osteoblast- and MSC-derived EVs has 
Figure 1. Publication trend of extracellular vesicles. Data were exported from Web of Science using the following criteria: (1) all 
databases, keywords (exosomes OR extracellular vesicle) and year range (1930–2017); (2) all databases, keywords (exosomes OR 
extracellular vesicle AND therapy) and year range (1930–2017).
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been shown to promote osteoblast differentiation and min-
eralisation both in vitro and in vivo.20 Thus, suggesting 
these bioactive particles are capable of promoting de novo 
mineralisation and may have considerable potential for 
driving skeletal tissue regeneration.
Current definition
EVs are defined as phospholipid-enclosed nanoparticles 
(30–2000 nm) that carry a complex and variable cargo of 
biological contents including proteins and nucleic acids. 
In the context of bone formation, vesicles will also con-
tain elements required to direct early mineralisation such 
as Ca2
+  and inorganic phosphate (Pi). These elements 
are thought to be derived from the cytoplasm or orga-
nelles such as mitochondria. The precise content and 
membrane composition of EVs are largely heterogene-
ous and dependent on cell type, location and condition of 
the local microenvironment.
To date, three different subtypes of EVs have been identi-
fied that are typically classified based on diameter and bio-
genesis (Table 1). Exosomes (30–150 nm) are formed within 
the endosomal network and are released when multivesicular 
bodies fuse with the plasma membrane. Microvesicles (50–
1000 nm) are generated by outward budding (blebbing) of 
the plasma membrane and will contain only local cytosolic 
proteins and nucleic acids. Larger vesicles termed apoptotic 
bodies (500–2000 nm) are released as fragments of dying 
cells and can often be distinguished by the presence of 
nuclear particulates as a consequence of karyorrhexis.21 
Notably, there is some discrepancy in the literature regarding 
the size range of each EV subtype, with considerable overlap 
noted in their size and content. As a consequence, studies 
that define exosomes purely by size are likely more repre-
sentative of a heterogeneous population comprising 
exosomes, small microvesicles and some additional non-
vesicular extracellular material – depending on the efficiency 
of isolation, this may include small membrane fragments and 
large extracellular proteins. It is of considerable importance 
that vesicles derived from different tissue and biofluid 
sources are defined in accordance with published guidelines 
presented by the ISEV.11 To further our understanding of the 
molecular composition of these EV subtypes, online 
resources are now available that provide a comprehensive 
and continually evolving database of protein, lipid and RNA 
analyses of EVs derived from a wide variety of cell and sam-
ple types. These can be found freely available online and 
include the databases Vesiclepedia (http://www.microvesicles.
org), EVpedia (http://student4.postech.ac.kr/evpedia2_xe/
xe) and ExoCarta (http://www.exocarta.org). Only by adher-
ing to implemented standards and contributing to the devel-
oping body of resources can we continue to generate rigorous 
Table 1. Definition and features of extracellular vesicles.
Features Exosomes Microvesicles Apoptotic bodies Matrix vesicles
Size (nm) 30–150 50–1000 500–2000 50–400
Other names Prostasomes
Tolerosomes
Dexosomes
Nanovesicles
Exosome-like vesicles
Microparticles
Blebbing vesicles
Shedding vesicles
Ectosomes
Microparticles
Microvesicles
Exosome-like vesicles
Exosomes
Ectosomes
Lipid 
composition
Enriched in phosphatidylserine, 
cholesterol, ceramide and other 
sphingolipids, LBPA and lipid rafts
Enriched in 
phosphatidylserine, 
phosphatidylethanolamine 
and sphingolipids
ND Enriched in 
phosphatidylserine, 
phosphatidylethanolamine 
and sphingolipids
Main protein 
markers
CD9, CD63, CD81, Alix, TSG101, 
Flotilin, Rab and ESCRT
CK18, MMP2, integrins, 
selectins and CD40
ND CD9, CD81, Flotilin, Rab, 
MMPs, HSPs, integrins, 
annexins and TNAP
Other cargo MicroRNA and other non-coding 
RNAs, mRNA, HSP70, HSP90, 
syntenin, ubiquitin, clathrin, VPS32, 
VPS4, protein kinases, β catenin, 
14-3-3, G proteins, peroxidases, 
pyruvate kinase, enolase, GAPDH, 
histones and ribosomal proteins
Other non-coding 
RNAs, mRNA, CD9, 
CD81, CD82, integrin, 
PECAM1, fibronectin, 
RAB, GTPases, annexins, 
GAPDH, ALIX, TSG101, 
ERK, PLD, VPS4, ALIX, 
TSG101, ERK, PLD, VPS4, 
actin, tubulin, histones and 
ribosomal proteins
Cell debris and 
organelles
MicroRNA and other 
non-coding RNAs, mRNA, 
actins, cofilin, moesin, 
myosin, heat shock 
proteins and chaperones, 
14-3-3, GTPases, histones 
and ribosomal proteins
Biogenesis Endosomal system as ILVs and 
secreted when MVBs fuse with 
the PM
Outward budding from 
the PM
Fragments of 
apoptotic cells
Population of exosomes 
and microvesicles
References 7, 16, 20 and 21 7, 16, 20 and 21 7, 16, 20 and 21 21 and 31
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and reproducible research as well as develop EV therapeu-
tics with translational potential.
Biological functions
The precise biological function of EVs is a reflection of 
the parental cell from which they were derived and the 
local microenvironment (e.g. inflammatory or hypoxic). 
Divergence in biological function can be demonstrated by 
the fact that they have been implicated in critical processes 
such as tissue formation as well as in pathological condi-
tions, including vascular calcification and many forms of 
cancer such as osteosarcoma.18,22 There have been studies 
showing that MSC-derived EVs have an anti-inflammatory 
and immunomodulatory capacity, promoting macrophage 
polarisation and proliferation.23 Furthermore, cardiac-
derived EVs have been shown to be powerful stimulators 
of angiogenesis in endothelial cells during a myocardial 
infarction so they potentially hold promise for applications 
such as cardiac vessel regeneration.24 EVs also play a 
prominent role within the nervous system, regulating mye-
lin formation, neuronal outgrowth and survival, receptor 
recycling and the removal of pathological proteins, which 
makes them promising candidates for neuronal regenera-
tion and the treatment of neuro-degenerative diseases.25 
However, the critical and long-defined contribution of 
these nanoparticles to early osteogenesis will be the focus 
of this review.
Role of EVs in hard tissue 
mineralisation
Matrix vesicles as sites of early mineral nucleation
Bone is the most ubiquitous mineralised tissue within verte-
brates and is composed of an inorganic multi-substituted 
hydroxyapatite. Although the biological and physicochemi-
cal properties of bone are well described, many of the pro-
cesses governing mineral formation, transport and 
deposition within the extracellular matrix (ECM) remain 
unclear. The pioneering studies of Anderson and Bonucci in 
1967 were the first to identify the presence of what they 
referred to as matrix vesicles (MVs) within hypertrophic 
cartilage. These vesicles were described as electron-dense 
bodies that became anchored within the developing ECM. 
The studies were the first to suggest that matrix mineralisa-
tion was not restricted to collagen fibrils.26 Since these ini-
tial findings, subsequent data have consolidated MVs as 
sites of initial calcification leading to the formation of early 
inorganic apatite crystals in epiphyseal cartilage in a range 
of species, including mice and guinea pigs.27 Within the 
evolving body of literature, MVs (Figure 2) refer to vesicles 
of varied size (50–400 nm) that reside in the pre-mineralised 
matrix of dentin, cartilage and bone.28 Although not com-
prehensively defined, MVs likely represent a mixture of 
exosomes and microvesicles containing specialised compo-
nents required to direct ECM mineralisation (Table 1).29–31 
Currently, no study has sought to define the independent 
contribution of distinct vesicle subsets during hard tissue 
mineralisation and few have begun to align MV theory 
within the context of the burgeoning field of EV biology.32 
Perhaps, our most advanced understanding of the biogenesis 
of MVs derives from a study by Boonrungsiman et al.,33 
where calcium phosphate–containing vesicles were found to 
associate with the mitochondria, thereby implicating spe-
cific intracellular transport pathways rather than simple 
membrane blebbing, characteristic of microvesicle biogen-
esis, as a mechanism for MV-mediated mineralisation. Even 
though the contribution of MVs to early mineralisation 
events in tissues such as calcifying cartilage, bone and den-
tine can no longer be disputed, the underlying mechanisms 
by which this is achieved remain unclear. Here, we will pre-
sent an overview of current opinion surrounding the role of 
MVs in physiological and pathological mineralisation.
MVs are enriched in membrane proteins with well-
defined roles in critical processes required for ECM min-
eralisation. These include the calcium-dependent 
phospholipid-binding annexin proteins (annexins II, V and 
VI) and enzymes including ectonucleotide pyrophos-
phatase/phosphodiesterase-1 (ENPP1) and alkaline phos-
phatase (ALP), which are required for maintaining the 
ratio of pyrophosphate (PPi) and inorganic phosphate (Pi) 
to regulate hydroxyapatite crystal formation26 and drive 
matrix remodelling (Figure 3).27 Under physiological con-
ditions, mineralisation is inhibited by PPi generated 
through the cleavage of nucleotide triphosphates by 
ENPP1.34 Inorganic Pi, derived through ALP-mediated 
hydrolysis of PPi, which drives mineralisation in both 
physiological and pathological conditions including vas-
cular calcification, is loaded into MVs via transmembrane 
phosphate transporter proteins, such as Pit1, where these 
ions associate with calcium localised to the phospholipid-
rich bilayer. Phospholipids comprising the MV membrane, 
including phosphatidylserine (PS), act in conjunction with 
membrane-binding proteins (e.g. annexins) to sequester 
Ca2
+  and PO4
3− ,  which drives the nucleation of immature 
mineral35 along with a less well-characterised pool of Ca2
+  
and Pi thought to be bound to luminal proteins.36 This 
association between Ca2
+ ,  PS and Pi forms the nuclea-
tional core complex, which has been hypothesised to func-
tion as an intra-vesicular niche for the formation of mature 
apatite. It is proposed that as mineral matures and becomes 
increasingly crystalline, it ruptures the EV membrane and 
associates with the underlying cartilaginous matrix,37 
thereby driving the early mineralisation events required 
for bone development and regeneration.
As stated, MV calcification is tightly linked with the 
presence of acidic membrane phospholipids.35 The pres-
ence of acidic phospholipids is significant in conferring 
membrane fluidity to promote fusion34 and uptake of 
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vesicles for intercellular communication, and in the transfer 
of signalling molecules between cells that comprise the 
skeletal niche.11 It also has significant implications when 
one considers current opinions surrounding the formation 
of mature and physiologically stable hydroxyapatite from 
an amorphous precursor.38 This transition is hypothesised 
to initiate from an amorphous precursor and proceed via a 
series of transient intermediate phases that include dical-
cium phosphate dihydrate (DCPD) and octacalcium phos-
phate (OCP) that are only stable at a sub-neutral pH. Based 
on our published findings, we hypothesise the presence of 
acidic phospholipids acts to generate a localised reduction 
in pH, thereby facilitating the stable formation of interme-
diate phases such as OCP that can be detected analytically.39 
Intriguingly, the presence of DCPD and OCP has also been 
associated with pathological calcification in which an 
acidic pH is frequently encountered. Furthermore, chemi-
cal analysis of the mineral deposited during pathological 
calcification, particularly in medial and intimal sites of 
coronary arteries, has led researchers to suggest an active 
vesicle-mediated mechanism similar to that underpinning 
physiological early bone formation.22 Vesicles localised 
to sites of vascular calcification derive from atrophying 
smooth muscle cells and recruited macrophages. The pro-
cess is inflammation-dependent and associated with the 
rupture of vulnerable plaques.40 Significantly, there is evi-
dence to suggest that not all plaque-associated vesicles 
are harmful, with non-calcifying fetuin-A+ and matrix Gla 
protein+ vesicles also identified. The presence of vesicles 
containing these calcification inhibitors is likely to be 
important for maintaining vascular health, and methods for 
enhancing their presence in patients at risk of atherosclero-
sis could have significant clinical implications.
Clinical perspective
A growing body of evidence has accumulated implicating 
EVs as complex biological mediators of tissue develop-
ment and regeneration. As such, there exists the potential 
to harness the regenerative capacity of these natural parti-
cles and exploit them to develop acellular yet complex bio-
logical approaches for driving tissue regeneration. At 
present, research into the regenerative application of EVs 
is in its infancy and the majority of documented research 
remains pre-clinical, with few clinical trials registered 
(Table 2). However, interest is rapidly growing with a 
Figure 2. Matrix vesicle (MV) cargo. Graphical representation of the matrix vesicle contents and membrane orientation of 
proteins, lipids and nucleic acids. Some of the listed components may be present in some matrix vesicles but not in others. For 
instance, in our previous study, we did not detect MHC complexes.
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number of recent publications outlining the potential ther-
apeutic utility of EVs for the regeneration of a wide range 
of tissues, including bone and cartilage. In this section, we 
shall discuss current research into EV-mediated tissue 
regeneration and highlight the promise and current limita-
tions of this approach.
There are several significant advantages in applying 
EVs for regenerative medicine when compared to conven-
tional biological approaches that typically incorporate a 
cell or growth factor to encourage endogenous tissue for-
mation. Firstly, vesicles may be superior to single 
approaches since they allow the delivery of multiple physi-
ologically relevant factors and, as they are naturally 
derived, confer enhanced biocompatibility and biostabil-
ity.41 The fact that EVs deliver multiple biomolecules to 
recipient tissues may also enable them to target several 
therapeutic pathways simultaneously, thus enhancing their 
therapeutic efficacy. Another advantage is that EVs do not 
contain replicative machinery, which is significant in that 
it may allow for genetic modification of the parent cell line 
without the transmission of manipulated DNA into the 
vesicle. This can be applied to confer advantages over pri-
mary cell-based approaches, such as decreased population 
doubling times and phenotypic stability, which have sig-
nificant implications when one considers the limited thera-
peutic window of primary cell therapies. The third benefit 
derives from the fact that EVs are not dynamic and cannot 
change phenotype, which has significant advantages when 
predicting therapeutic outcomes, ensuring reproducibility 
and reducing the risk of neoplastic transformation. In addi-
tion, the relatively small diameter of EVs means that they 
are less likely to become trapped inside the lungs, liver and 
spleen if administered intravenously and their innate hom-
ing ability increases the likelihood of these drugs reaching 
the target site. This makes EVs appealing as vehicles for 
loading pharmaceuticals and/or other therapeutic com-
pounds to reduce drug clearance rates, with the aim of 
enhancing or extending their efficacy. In addition, by tai-
loring vesicle properties such as lipid composition, there 
may be the opportunity to further improve the stability of 
the nanoparticle while in circulation and increase their 
half-life when delivered locally or intravenously. Overall, 
EVs manufactured ex vivo may offer many of the benefits 
of a cell-based approach while avoiding the inherent pit-
falls. The benefits of EVs as naturally derived particles for 
enhancing tissue regeneration have been documented in a 
wide range of tissues. We shall next explore current litera-
ture surrounding the application of EVs in soft and hard 
tissue regeneration.
The majority of studies applying EVs for regenerative 
applications have utilised vesicles derived from stem cells, 
including MSCs, embryonic stem cells (ESCs) and other 
tissue-specific stem cells due to their anticipated immuno-
compatibility and documented roles as paracrine mediators 
of tissue repair.42 To date, MSC-derived EVs have been 
shown to enhance proliferation, inhibit apoptosis, decrease 
inflammation and promote processes such as angiogenesis 
and cellular reprogramming.43 In animal studies of myocar-
dial ischaemia, the delivery of MSC-derived EVs has cardio-
protective effects, promoting angiogenesis that improved 
recovery and reduced infarct site in laboratory animals with 
experimental myocardial infarction.44 Similarly, delivery of 
ESC vesicles enriched in miRNA-290-295 was found to pro-
mote neovascularisation and enhance cadiomyocyte survival 
and function following myocardial infarction.45 In a separate 
study, cutaneous burns treated with MSC-derived exosomes 
demonstrated accelerated cell proliferation and re-epithelial-
isation through the delivery of Wnt4 and downstream β-
catenin nuclear translocation.46 These promising particles 
have also been shown to promote myogenesis and muscle 
regeneration in an in vivo model of skeletal muscle injury. 
Interestingly, in this study, MSC-derived vesicles were found 
to contain a relatively low concentration of muscle-repair 
proteins, such as vascular endothelial growth factor (VEGF) 
and interleukin (IL)-6, with the regenerative effects primar-
ily attributed to the presence of small RNAs, including 
miRNA-494.5 Finally, in an in vitro model of inflammatory 
osteoarthritis, bone marrow–derived and adipose-derived 
MSC EVs were found to inhibit the action of pro-inflamma-
tory mediators including ILs and tumor necrosis factor-alpha 
(TNFα)-induced collagenase activity.19,47 This list presents 
several significant outcomes to date but is by no means 
Figure 3. Schematic diagram of the mineralisation process. 
NPP1 inhibits mineralisation by generating PPi by catalysing 
extracellular ATP. TNAP promotes mineralisation by 
hydrolysing PPi into inorganic phosphate ions, which are in 
turn transported to the matrix vesicle (MV) through phosphate 
transporters such as Pit1. Conversely, ANK transports PPi 
from the MV into the developing ECM. Annexins function 
as calcium channels, transporting Ca2
+  inside the MV and 
localise Ca2
+  and PO4
3−  in a nucleational core complex, which 
facilitates mineral nucleation and transition to a crystalline 
hydroxyapatite. This is hypothesised to eventually rupture 
the vesicle membrane and propagate within the collagenous 
extracellular matrix.
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comprehensive with additional therapeutic effects observed 
in a variety of other tissues including the kidneys, liver and 
nervous system. For a comprehensive overview of the poten-
tial of EVs for soft tissue regeneration, we recommend the 
following articles by Chen et al.48 and Lamichhane et al.49
To date, the considerable potential of an EV-based 
approach to regenerative medicine has perhaps been most 
comprehensively demonstrated in the skeletal system with 
prospective applications for enhancing fracture repair and 
in treatment of degenerative conditions, including osteopo-
rosis. Osteoblast-derived vesicles isolated from actively 
differentiating cultures are enriched in metalloproteinases 
conducive to matrix remodelling and calcification.50 These 
vesicles have defined roles in regulating osteoclastogenesis 
through the delivery of the pro-osteoclastic cytokine, recep-
tor activator of nuclear factor κ-B ligand (RANKL). 
Stimulation of osteoblasts with parathyroid hormone has 
been shown to further enrich EVs with RANKL.51 As such, 
there exists the potential to manipulate culture conditions 
ex vivo to generate biocompatible and therapeutically 
enhanced vesicles that are biologically programmed to 
target osteoclasts for the treatment of osteoporosis. 
Alternatively, EVs can be modified to modulate osteoclast 
activity post-isolation through the active loading of anti-
osteoclast drugs, such as zoledronate or dasatinib. In addi-
tion to osteoclast modulation, we have previously shown 
that when administered within MSC cultures, osteoblast-
derived EVs act as sites for extracellular nucleation of cal-
cium phosphate, enhancing mineralisation when compared 
to a current gold standard, BMP-2.33 MSC-derived EVs 
have been shown to stimulate osteoblastic activity and dif-
ferentiation through miR-196a, miR-27a, miR206 expres-
sion and bone regeneration in vivo.20 In addition, the 
injection of MSC-derived exosomes has been shown to 
promote healing in a murine CD9−/− femur fracture model 
– a model known to produce reduced levels of exosomes.52 
Evolving the concept of EV-based regenerative medicine 
even further, a recent study combined MSC-derived vesi-
cles with a scaffold composed of decalcified bone matrix. 
The regenerative effects of EVs were monitored following 
subcutaneous implantation in mice and represented the first 
time that EVs had been delivered in combination with a 
biological scaffold. Outcomes were positive with enhanced 
angiogenesis and mineralisation observed in vivo.53 A sub-
sequent study combined EVs with a poly(lactic-co-glycolic 
acid) (PLGA) scaffold by immobilising them in polydopa-
mine coating. The scaffold was subsequently implanted in 
a critical size calvarial defect with sustained release of EVs 
observed and immunohistochemical evidence of bone 
regeneration.54 The aforementioned studies highlight the 
considerable advances made in EV-focused regenerative 
medicine. However, these approaches are the first to be 
Table 2. Registered clinical trials in clinicaltrials.gov.
Row Status Study title Conditions Interventions Locations
1 Completed Effect of exosomes derived 
from red blood cell units 
on platelet function and 
blood coagulation
Blood coagulation 
and platelet 
function
Other: in vitro study University Hospital 
Frankfurt, Frankfurt 
am Main, Hessen, 
Germany
2 Completed Phosphate in blood 
pressure regulation
Hypertension Dietary supplement: sodium 
phosphate
Drug: sevelamer, sodium 
bicarbonate and sodium 
chloride
University Hospital 
Zurich, Nephrology, 
Zurich, ZH, 
Switzerland
3 Completed Pilot immunotherapy trial 
for recurrent malignant 
gliomas
Malignant glioma 
of brain
Drug: IGF-1R/AS ODN
Device: biodiffusion chamber
Thomas Jefferson 
University Hospital; 
Jefferson Hospital 
for Neurosciences, 
Philadelphia, PA, USA
4 Completed Influence of high and low 
salt on exosomes in the 
urine
Healthy Dietary supplement: high-salt 
diet followed by low-salt diet
Dietary supplement: low-salt 
diet followed by high-salt diet
University of Southern 
Denmark, Odense, 
Denmark
5 Completed Influence of rosiglitazone 
on the diuretic effect of 
furosemide and amiloride
Insulin resistance Drug: rosiglitazone versus 
placebo
Drug: response (sodium 
excretion) to amiloride 
infusion
Drug: response (sodium 
excretion) to furosemide 
infusion
Radboud University 
Nijmegen Medical 
Centre, Nijmegen, 
Netherlands
Keyword: exosomes. The inclusion criteria were the following: recruitment status (completed), age (all), sex (all) and study type (interventional).
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published in this novel therapeutic area. As such, there is 
considerable scope for development and refinement, as we 
shall now discuss.
Despite the considerable benefits offered by an EV-based 
approach to regenerative medicine, there are several limita-
tions that need to be overcome before this method can 
become a clinical reality. For a comprehensive overview of 
current barriers to translation, the authors recommend a pre-
vious publication by Davies and Rafiq.55 At present, the 
most limiting factors restricting the advancement of EV 
therapies can be grouped into the following categories:
•• Devising efficient methods for the scaling and har-
vest of EVs;
•• Identifying markers of therapeutic potency;
•• Generating a consistent and homogeneous EV 
product;
•• Storage, biosafety, biodistribution and pharma- 
cokinetics;
•• Positioning regenerative EV therapies within the 
current regulatory framework.
Manufacturing large numbers of therapeutically viable 
EVs at scale is essential if we are to meet clinical and com-
mercial demand. This represents a challenging task, par-
ticularly when using a primary cell source with a limited 
window of passage. The task becomes more demanding 
when we consider the complex media formulations that are 
typically employed in EV research and the commercial 
requirement for chemically defined and serum-free systems 
that maintain EV yield and function. To date, hollow fibre 
bioreactors have been most applied for this purpose. These 
reactors apply a fibre-based cartridge with a molecular 
weight cut off to retain EVs while allowing the free diffu-
sion of nutrients and waste. It has been postulated that the 
application of hollow fibre reactors could also address 
issues surrounding the need for serum-free media, since 
any vesicles contained within the serum fraction will 
exceed the molecular cut off and, as such, be excluded from 
the condition medium.56 We anticipate that other reactor 
technologies, including stirred tank bioreactors, will also 
demonstrate utility in EV manufacture given their legacy 
in the production of numerous biologics, as well as the 
potential to combine these systems with microcarriers.57 
Furthermore, these reactors can be operated with spin fil-
ters to allow for the retention of cells and small particles 
including EVs. For a comprehensive overview of the appli-
cation of bioreactors for EV manufacture, we recommend 
the recent publication by Colao et al.58 as well as the afore-
mentioned publication by Davies and Rafiq.55 At present, 
there is limited knowledge of how the cell culture microen-
vironment impacts EV production and content. As such, 
there will be a need to comprehensively evaluate the effects 
of bioreactor systems designed for cell biomanufacturing 
on EV production.59
In addition to manufacturing large concentrations of 
EVs, it is essential that methods are in place for their effi-
cient isolation. At present, several approaches have been 
applied to isolate EVs from cell culture media as well as a 
variety of biofluids. These include differential UC, ultrafil-
tration, sucrose density gradient sedimentation, size exclu-
sion chromatography, tangential flow filtration, kit-based 
precipitation and affinity-based selection. A critical over-
view of several of these techniques for the isolation of EVs 
from serum can be found in the publication of Buschmann 
et al.60 All these methods have advantages and disadvan-
tages and are highly dependent on the availability of spe-
cialised laboratory equipment and relevant in-house 
technical expertise. Perhaps, the most ubiquitously applied, 
and certainly the one most frequently utilised for the isola-
tion of EVs from hard tissues such as bone, is differential 
UC. Unlike the other methods listed, UC can be applied to 
isolate EVs from large volumes of conditioned culture 
medium. As such, it currently represents the most viable 
option for the direct isolation of high concentrations 
required for regenerative applications. However, UC is a 
specialised, time consuming, laborious and inefficient pro-
cess. Furthermore, variation can be introduced depending 
on the type of centrifuge and rotor applied. For example, a 
shorter sedimentation path length in the fixed angle com-
pared to the swinging bucket rotor will result in a faster 
sedimentation rate for peripheral vesicles. As a conse-
quence, it is necessary to adjust the duration and force of 
centrifugation depending on the model and type of centri-
fuge used.61 Consequently, different isolation methods will 
yield EVs of variable heterogeneity, making it difficult to 
compare results between studies.55 As interest in therapeu-
tic EVs continues to increase, it is critical that we imple-
ment consistent and readily available methods for 
generating large concentrations of EVs that retain maxi-
mal therapeutic efficacy. Recently, a promising method 
has been developed at the National University of Singapore, 
which applies centrifugal microfluidics for the label-free 
isolation of microvesicles.62 This approach is appealing in 
that can be applied to efficiently isolate microvesicles over 
short time periods (typically minutes) using only a stand-
ard bench-top centrifuge. However, at present, the technol-
ogy can only been applied for the isolation of EVs from 
small sample volumes (µL). As such, further development 
will be required if this approach is to be used for high-
volume samples required for regenerative applications.
Other factors that need to be clarified before EV thera-
pies can begin to be successfully translated related to 
nomenclature and the comprehensiveness of methods 
applied for EV characterisation and quantification of batch 
homogeneity. Current standards have been published in a 
position statement outlining the minimal experimental cri-
teria required for defining EVs.11 However, such a defini-
tion does not serve to provide a quantitative measurement 
of therapeutic efficacy, which will no doubt depend on the 
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cell from which the EVs are derived and the purpose of 
their application. Such a measure can perhaps only be 
achieved through the identification of specific surface or 
intra-vesicular markers that can be measured during or 
post-isolation. In a previous study, we identified a correla-
tion between certain calcium-binding annexin proteins 
(annexins I, II and VI) and EV-mediated mineralisation in 
human stem-cell cultures.39 However, further work will be 
necessary to determine whether selecting for annexin-
enriched EV populations can enhance hard tissue regenera-
tion in vivo. In addition, the application of antibody-based 
selection methods will pose further challenges when 
applied for the isolation of large concentrations of EV prod-
uct at scale. Reflecting on this last comment, it may be 
advantageous to employ label-free methods that provide 
non-specific biochemical fingerprints that align with 
known measures of therapeutic potency. Such methods 
could include Raman spectroscopy, which has shown suc-
cessful application for the biochemical profiling of tissue-
specific differences in MSC-derived EVs.63 Once the MoA 
has been identified and accurate markers of potency 
defined, we can begin to evaluate critical pre-clinical 
parameters such as dosage, toxicity and biodistribution. It 
will also be pertinent to determine how EVs can be stored 
to maximise biological potency and minimise operational 
burden in the clinic. There is evidence to indicate sustained 
viability and functionality of human urinary exosomes 
when stored at −80°C in the presence of a cocktail of pro-
tease inhibitors.64 This evidence is encouraging given that it 
may reduce costs associated with more complex cryo-pres-
ervation procedures that are a requirement for cell-based 
therapies. However, studies will be required to determine 
the effects of long-term storage on EVs isolated from other 
biofluids and cell sources, including osteoblasts.
Finally, regulation surrounding the application of EV 
therapeutics is at present unclear. It has been proposed 
that EV-based therapies will likely fall under the category 
of biological medicines unless delivering trans-gene prod-
ucts derived from genetically manipulated cells in which 
case they will fall under the category of Advanced Therapy 
Medicinal Products (ATMPs).65 However, regulatory 
classification will remain challenging until the MoA by 
which EVs exert their therapeutic effects is established. It 
is likely that this will vary between applications and may 
require assessment on a case-by-case basis. For a compre-
hensive review of current limitations surrounding the 
advancement of vesicle-based therapeutics in regenera-
tive medicine and beyond, we recommend the article by 
Gimona et al.65
Summary and conclusion
EVs offer considerable value as a biological yet acellular 
approach for driving endogenous tissue regeneration. 
These complex particles offer significant advantages over 
growth factor and cell-based approaches and, to date, posi-
tive outcomes have been demonstrated in a variety of soft 
and hard tissues. Within the last 3 years, several groups 
have shown that these EVs can be combined with a variety 
of biocompatible scaffolds and implanted in vivo to drive 
de novo ossification and tissue vascularisation. However, 
before the considerable potential of EVs can become a 
clinical reality, inherent variability relating to methods of 
EV isolation and characterisation need to be standardised.
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